No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CYTK250117P40000
- 0.34
- 0.000.00%
15min DelayTrading Dec 3 15:29 ET
0.00High0.00Low
0.00Open0.34Pre Close0 Volume977 Open Interest40.00Strike Price0.00Turnover54.95%IV18.88%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.34Extrinsic Value100Contract SizeAmericanOptions Type-0.0750Delta0.0202Gamma195.56Leverage Ratio-0.0191Theta-0.0024Rho-14.66Eff Leverage0.0181Vega
Intraday
- 5D
- Daily
News
Cytokinetics Says European Regulator Validated Its Application for Cardiomyopathy Drug Candidate
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating
Express News | Cytokinetics Inc - FDA Sets Pdufa Target Action Date for Aficamten Nda as Sept 26, 2025
Express News | Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)
Why Cytokinetics Stock Was a Nearly 5% Winner Today